Tag: Antifibrotic

According to recent guidelines presented at Digestive Disease Week 2025, a paradigm shift is underway in the management of portal hypertension, with a stronger endorsement of carvedilol as a preferred medication. While no single medication has been designated definitively as "what is the new drug for portal hypertension?", research is actively focused on targeted therapies and optimizing existing treatments.

Metformin is one of the most widely prescribed oral medications globally for managing type 2 diabetes. While many patients wonder about the potential respiratory side effects of their medications, available evidence indicates that metformin does not cause pleural fibrosis; in fact, some studies suggest it may have protective, anti-fibrotic properties.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with a median survival of just 3 to 5 years without treatment. As one of only two FDA-approved medications for this condition, pirfenidone is an antifibrotic agent that plays a critical role in slowing the decline of lung function.

Idiopathic Pulmonary Fibrosis (IPF) affects up to 140,000 people in the United States, with treatments aimed at slowing its progression. For those prescribed pirfenidone, a key question is: **how long does it take for pirfenidone to work?** The effects are gradual, often taking several months.

Idiopathic pulmonary fibrosis (IPF) affects 13 to 20 per 100,000 people worldwide [1.10.1, 1.10.5]. For those diagnosed, a key question is: is nintedanib long term use a viable strategy? The evidence points to yes, as it is designed for chronic disease management.

Idiopathic pulmonary fibrosis (IPF) affects up to 80,380 people in the United States, with about 25,000 new cases yearly. This article explores a key treatment, explaining **how does pirfenidone work** to slow the disease's progression.

In 2014, the FDA approved two new antifibrotic medications, Esbriet (pirfenidone) and Ofev (nintedanib), on the same day for treating idiopathic pulmonary fibrosis (IPF). This milestone provided new hope for patients with this progressive and fatal lung disease. With two options available, the question of which is more effective, Esbriet or Ofev?, became a central topic of discussion among patients and healthcare providers.

Clinical trials, such as the INPULSIS-1 and INPULSIS-2 studies, demonstrated that nintedanib significantly reduces the rate of decline in lung function for patients with idiopathic pulmonary fibrosis. This potent antifibrotic medication helps manage the disease by intervening in the cellular processes that cause scarring.

Affecting approximately 140,000 Americans, Idiopathic Pulmonary Fibrosis (IPF) is a serious lung condition [1.4.1]. A key question for patients is: **Is Esbriet being discontinued?** While the brand-name drug remains available, the treatment landscape has significantly changed with the introduction of generic pirfenidone [1.3.1, 1.4.3].

In the United States, idiopathic pulmonary fibrosis (IPF) affects an estimated 100,000 people, with 30,000 to 40,000 new cases diagnosed annually. This article explores a key treatment: **what is the drug Esbriet used for?**